マイキャン・テクノロジーズ Product Lineup

Our company has realized a highly accurate "contract service for drug evaluation" through the mass production of human leukocytes using iPS technology, enabling rapid and reliable drug development. In the fields of infectious diseases and immunology/oncology research and evaluation, obtaining stable quantities of quality blood cells has been a significant bottleneck. However, we have successfully addressed this issue by using iPS technology (regenerative medicine technology) to mass-produce "stimulus-naive myeloid cells (dendritic cells)" with identical genetic information. This has dramatically improved the accuracy and speed of drug evaluation. We can also produce blood cells from individual blood samples, allowing for the simultaneous realization of a simple evaluation system and a wide range of evaluation designs. 【Our Strengths】 - Ability to procure myeloid cells, which are typically scarce, in large and stable quantities - Use of "stimulus-naive dendritic cells," ideal for research and evaluation - Capability to produce blood cells from provided blood samples - Possibility to construct evaluation systems using mature dendritic cells as antigen-presenting cells *For more details, please download the PDF or feel free to contact us.

• Other contract services
• Other analysis and evaluation services

Our company exclusively uses myeloid cells derived from iPS cells, allowing for highly accurate measurements of neurotransmitters and cytokines induced by stimulation. The reliability of test results and the flexibility of evaluation design have dramatically increased, significantly reducing measurement time and costs. This has led to a groundbreaking evaluation service that contributes to faster product development. Please feel free to contact us if you have any requests. 【About Blood Cells】 ■ Dendritic cells produced using regenerative medicine technology from healthy human cells: "Mylc" blood cells ■ These "Mylc" blood cells, which possess the same genes and are controlled in an undifferentiated state (immature) before external stimulation, provide pure and clear responses to stimuli in tests, resulting in highly reliable test results. ■ The responses are very close to human in vivo reactions, and there are no issues with the reproducibility of results. *For more details, please download the PDF or feel free to contact us.

• Other analysis and evaluation services
• Other contract services

"Mylc" is a human dendritic cell produced using iPS cell technology (regenerative medicine technology), controlled in an ideal "immature (pre-stimulation)" state for research and evaluation. It can reproduce the same genetic information and state multiple times, significantly improving the accuracy and applicability of pharmaceutical evaluations. Additionally, it allows for the acquisition of blood cells in the ideal state in any required quantity, enabling smooth execution of research and development as well as efficacy evaluations, thus accelerating the development process. 【Features】 - Homogeneous blood cells with identical genetic information - Free control over appropriate differentiation stages - Large-scale and stable production and supply possible *For more details, please download the PDF or feel free to contact us.

• Human cells